Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke

Thang S. Han1 · Giosue Gulli2 · Christopher H. Fry3 · Brendan Affley2 · Jonathan Robin4 · David Fluck5 · Puneet Kakar6 · Pankaj Sharma1,7

Accepted: 27 June 2021 / Published online: 13 July 2021 © The Author(s) 2021

Abstract
Complications following thrombolysis for stroke are well documented, and mostly concentrated on haemorrhage. However, the consequences of patients who experience any immediate thrombolysis-related complications (TRC) compared to patients without immediate TRC have not been examined. Prospectively collected data from the Sentinel Stroke National Audit Programme were analysed. Thrombolysis was performed in 451 patients (52.1% men; 75.3 years ± 13.2) admitted with acute ischaemic stroke (AIS) in four UK centres between 2014 and 2016. Adverse consequences following immediate TRC were assessed using logistic regression, adjusted for age, sex and co-morbidities. Twenty-nine patients (6.4%) acquired immediate TRC. Compared to patients without, individuals with immediate TRC had greater adjusted risks of: moderately-severe or severe stroke (National Institutes of Health for Stroke Scale score ≥ 16) at 24-h (5.7% vs 24.7%, OR 3.9, 95% CI 1.4–11.1); worst level of consciousness (LOC) in the first 7 days (score ≥ 1; 25.0 vs 60.7, OR 4.6, 95% CI 2.1–10.2); urinary tract infection or pneumonia within 7-days of admission (13.5% vs 39.3%, OR 3.2, 95% CI 1.3–7.7); length of stay (LOS) on hyperacute stroke unit (HASU) ≥ 2 weeks (34.7% vs 66.7%, OR 5.2, 95% CI 1.5–18.4); mortality (13.0% vs 41.4%, OR 3.7, 95% CI 1.4–11.1); moderately-severe or severe disability (modified Rankin Scale score ≥ 4) at discharge (26.8% vs 65.5%, OR 4.7, 95% CI 2.1–10.9); palliative care by discharge date (5.1% vs 24.1%, OR 5.1, 95% CI 1.7–15.7). The median LOS on the HASU was longer (7 days vs 30 days, Kruskal–Wallis test: $\chi^2 = 8.9, p = 0.003$) while stroke severity did not improve (NIHSS score at 24-h post-thrombolysis minus NIHSS score at arrival = − 4 vs 0, $\chi^2 = 24.3, p < 0.001$). In conclusion, the risk of nosocomial infections, worsening of stroke severity, longer HASU stay, disability and death is increased following immediate TRC. The management of patients following immediate TRC is more complex than previously thought and such complexity needs to be considered when planning an increased thrombolysis service.

Keywords Acute ischaemic stroke · Disability · Symptomatic intracranial haemorrhage · Mortality · Nosocomial infections

Thang S. Han
thang.han@rhul.ac.uk

1 Institute of Cardiovascular Research, Royal Holloway University of London, Egham TW20 0EX, UK
2 Department of Stroke, Ashford and St Peter’s NHS Foundation Trust, Chertsey GU9 0PZ, UK
3 School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK
4 Department of Acute Medicine, Ashford and St Peter’s NHS Foundation Trust, Chertsey GU9 0PZ, UK
5 Department of Cardiology, Ashford and St Peter’s NHS Foundation Trust, Chertsey GU9 0PZ, UK
6 Department of Stroke, Epsom and St Helier University Hospitals, Epsom KT18 7EG, UK
7 Department of Clinical Neuroscience, Imperial College Healthcare NHS Trust, London W6 8RF, UK

Springer
Highlights

- In patients undergoing thrombolysis, compared with those without complications, patient with thrombolysis-related complications had 4 fold increase in early adverse outcomes.
- Stayed longer on hyperacute stroke units and mortality.
- They also had 5-fold increase risk of disability and requiring palliation at discharge.

Introduction

Intravenous recombinant tissue plasminogen activator (rtPA), has been the standard thrombolysis treatment of acute ischaemic stroke (AIS) since the early 2000s in Europe [1, 2] and a few years earlier in the US [3]. The first decade into the treatment saw an increasing trend in the number of patients receiving thrombolysis [4, 5], subsequently followed by addition of this treatment to all eligible patients over 80 years of age [6, 7]. In recent years, the rate of thrombolysis administration has remained static in most countries where the proportion of all patients with stroke receiving thrombolysis (11–12%) has changed little between 2013 and 2020, well below the long-term target of 20% set by National Health Service (NHS) England [8]. Although outcomes have improved over the years [9, 10], many thrombolysis-related complications (TRC) remain a major issue, ranging from brain haemorrhage in the immediate stage to nosocomial infections, cardiac complications, seizures and deep vein thrombosis in later stages of treatment [11, 12]. The most feared immediate TRC is symptomatic intracranial haemorrhage (ICH), occurring in 7.7% of those treated with an rtPA compared to 1.8% in controls [11]. The Sentinel Stroke National Audit Programme (SSNAP) data of stroke patients in England and Wales published in 2013 reported symptomatic ICH occurred in 4.3% of patients < 81 years and 5.1% ≥ 81 years, followed by orolingual angioedema (<2%) and extra-cranial bleed (<1%) after thrombolysis [13].

Despite intensive research on the safety of rtPA, little is known about adverse consequences among patients who acquired immediate TRC. Most studies have investigated with the immediate outcome of, and from, bleeding following thrombolysis. In this study, we examined the association of immediate (and any) TRC with the risk of adverse outcome including: severity of stroke; ICH; nosocomial infections; worst level of consciousness (LOC) in the first 7-days following initial admission for stroke; length-of-stay (LOS) on hyperacute stroke units (HASUs); in-patient mortality and disability at discharge; as well as the level of support on discharge, including help with activities of daily living, new care home arrangement and palliation.

Methods

Study design, participants and setting

We performed analysis of prospectively collected data from the UK national register of stroke care (SSNAP). The data comprised clinical characteristics and care quality determinants of patients admitted to acute care hospitals in England and Wales [14]. Data from the present study were gathered from 3309 patients (2758 with AIS) admitted to four major UK hyperacute stroke centres in South East England between January 2014 and February 2016 [15, 16]. The sites included Ashford and St Peter’s (n = 1038), Frimley Park (n = 1010), Royal Surrey County (n = 612) and Epsom General (n = 649) hospitals. Outcome data from 451 (16.4% of AIS) consecutive patients undergoing thrombolysis were analysed in the present study. SSNAP has approval from the Confidentiality Advisory Group of the Health Research Authority to collect patient data under section 251 of the NHS Act 2006 (no additional ethical approval was required).

Socio-demographic factors and medical history

Demographic data were collected and documented by stroke consultants and nurse specialists; including age at arrival, gender and coexisting morbidities: atrial fibrillation (AF), hypertension, congestive heart failure, diabetes mellitus and previous stroke [14–16].

Stroke diagnosis and severity

Stroke was diagnosed based on clinical presentation and brain imaging [14–16]. The severity of stroke symptoms at arrival was assessed by the National Institutes of Health for Stroke Scale (NIHSS) with a score range from no symptoms to severe stroke symptoms (NIHSS score = 0 to 42) [17].

Thrombolysis and immediate TRC

Thrombolysis using the rtPA agent alteplase was performed in patients who fulfilled criteria for therapy including confirmed diagnosis of AIS, time from onset and without contra-indications [14–16]. TRC such as severe hypertension, acute orolingual angioedema, anaphylaxis and hyperacute haemorrhage were defined clinically. Identification of symptomatic ICH was based on imaging evidence of intracerebral...
haemorrhage in conjunction with a significant decline in neurological function [13, 14].

**Adverse consequences after immediate TRC**

*Nosocomial infections* including urinary tract infection (UTI) and pneumonia acquired in hospital within 7-days of admission were recorded. The worst LOC scores in the first 7-days following initial admission for stroke were graded as: 0 = Alert keenly responsive, 1 = Not alert but arousable by minor stimulation, 2 = Not alert but require repeated stimulation to attend, and 3 = Respond only with reflex motor or autonomic effects/totally unresponsive [14]. The length of stay on HASUs as well as in-patient mortality were also documented. Changes in severity of stroke after thrombolysis were calculated as the difference between NIHSS score at 24-h minus NIHSS score on arrival.

**Disability at discharge** was evaluated using modified Rankin Scale (mRS) scores: 0 = no symptoms at all; 1 = no significant disability despite symptoms, able to carry out all usual duties and activities; 2 = slight disability, unable to carry out all previous activities but able to look after their own affairs without assistance; 3 = moderate disability; requiring some help, but able to walk without assistance; 4 = moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance; 5 = severe disability, bedridden, incontinent and requiring constant nursing care and attention [18, 19].

**Level of care support planned at discharge**

Details of the planned level of care support were recorded including: help for activities for daily living, the frequency of home visits, and joint care-planning between health and social care for post-discharge management. Information on decision to introduce palliative care by discharge date, as well as discharge to a new care home, either on a temporarily or permanent basis was also documented [19].

**Categorisation of variables**

Dichotomisation was applied for AF, congestive heart failure, hypertension and diabetes, type of stroke, and in-patient infections and mortality according to the presence or absence of any history of the condition. Moderately-severe to severe disability at discharge was defined as an mRS score ≥ 4. Moderately-severe to severe stroke on arrival and at 24-h was defined as an NIHSS score ≥ 16. Prolonged LOS on HASU was defined as those who stayed longer than 2 weeks. Severity of LOC scale during the first 7-days of initial admission was dichotomised into two groups: group 1 with a score of 0 (alert keenly responsive), and group 2 with a score of ≥ 1 (ranging from not alert but arousable by minor stimulation to respond only with reflex motor or autonomic effects/totally unresponsive).

**Statistical analysis**

Chi-squared tests were used to assess the proportions of individuals with adverse consequences in relation to different study groups (with or without immediate TRC), and Kruskal–Wallis tests were used to assess group differences in LOS on HASUs and changes in stroke severity. Multivariable logistic regression was conducted to estimate the risk of severe stroke at 24-h, prolonged LOS on HASU, in-patient mortality, UTI and pneumonia within 7-days of admission, severity in LOC scale in the first 7-days, disability at discharge and palliative care by discharge date (dependent variables) from patients with immediate TRC using patients without immediate TRC as the reference group (independent variable). The results are presented as three models: model 1, unadjusted; model 2, adjusted for age, sex and co-morbidities (AF, congestive heart failure, hypertension, diabetes and previous stroke), and model 3, as in model 2 plus time from onset to thrombolysis and NIHSS on arrival, and expressed as odds ratios (OR) and 95% confidence intervals (CI). Analyses were performed using IBM SPSS Statistics for Windows, V.25.0 (IBM Corp., Armonk, NY, USA). The null hypothesis was rejected when \( p < 0.05 \).

**Results**

Data from 235 men and 216 women aged 75.3 years (± 13.2) were analysed. Twenty-nine patients (6.4%) developed immediate TRC, mostly symptomatic intracranial haemorrhage (n = 18) (Table 1). The median age (IQR) for

| Table 1 Frequency of immediate thrombolysis-related complications amongst 451 patients undergoing thrombolysis for ischaemic stroke |
| --- |
| n | % |
| Symptomatic intracranial haemorrhage | 18 | 4.0 |
| Orolingual angioedema | 2* | 0.4 |
| Extracranial bleed | 2 | 0.4 |
| Abdominal pain | 1 | 0.2 |
| Anaphylaxis | 1 | 0.2 |
| Bleeding gums | 1 | 0.2 |
| Epistaxis | 2 | 0.4 |
| Gastrointestinal bleed | 1 | 0.2 |
| Intracerebral bleed | 1 | 0.2 |
| Asymptomatic haemorrhage | 1 | 0.2 |
| All patients with complications | 29 | 6.4 |

*One patient with both intra-cranial haemorrhage and orolingual angioedema
patients with immediate TRC was 83 years (75–87.5) and for those without was 77 years (67–85) (Kruskal–Wallis test: $\chi^2 = 5.8, p = 0.016$). The proportions of men (51.2%) and women (48.8%) were similar between groups, while there was a male predominance in the group with immediate TRC (65.5% men: 34.5% women). The rates of AF among patients with immediate TRC were higher (37.9% vs 18.5%, $\chi^2 = 6.5, p = 0.011$), but no significant group differences in the use of anticoagulation therapy for AF: 36.4% vs 27.3%, $\chi^2 = 3.3, p = 0.192$. There were no differences in the rates of other co-existing morbidities including congestive heart failure, hypertension, diabetes and previous stroke, or the rates of patients with moderately-severe to severe NIHSS scores ($\geq 16$). The proportions of individuals with TRC were higher for a number of adverse consequences in hospital. These included moderately-severe to severe stroke 24-h after thrombolysis, LOC scores $\geq 1$ in the first 7-days, and pneumonia within 7-days of admission. There were also higher proportions of HASU stay for $\geq 2$ weeks, mortality in hospital and moderately-severe to severe disability (mRS score $\geq 4$) on discharge, as well as requirement for palliative care by the date of discharge in this group (Table 2). Compared to patients without TRC, the LOS on HASU was longer by about 6 days for those who had the immediate TRC; Kruskal–Wallis test: $\chi^2 = 8.9, p = 0.003$ (Fig. 1).

The median (IQR) NIHSS score on arrival was 12 (7–18) and at 24-h post-thrombolysis was 6 (2–12) for those without immediate TRC; corresponding values for those with immediate TRC were 12 (6–18) and 14 (6–20). The change in NIHSS score at 24-h after thrombolysis minus NIHSS score on arrival were $-4$ ($-8$ to $-2$) for patients without immediate TRC and 0 ($-1$ to 6) for those with immediate TRC was significant: a difference of $-4$ ($-8$ to $-1$); Kruskal–Wallis test: $\chi^2 = 24.3, p < 0.001$ (Fig. 2).

The proportions of patients with a LOC score in first 7-days of 0 (alert) were higher in patients without immediate TRC (75%) compared to those with immediate TRC (39.3%). Conversely, the proportions of patient with immediate TRC rose progressively with increasing LOC scores, peaking at 35.7% for a score of 3 (respond only with reflex motor or autonomic effects/totaly unresponsive), compared to 7.2% in those without immediate TRC (Fig. 3).

### Table 2: Proportions of adverse outcomes in 451 patients without (n = 422) and with (n = 29) post-thrombolysis complications

| Co-existing morbidities               | Immediate thrombolysis-related complications | Group difference |
|---------------------------------------|---------------------------------------------|------------------|
|                                       | Not present (%) | Present (%) | $\chi^2$ | $p$     |
| Atrial fibrillation                   | 18.5            | 37.9       | 6.5     | 0.011  |
| Congestive heart failure              | 4.7             | 6.9        | 0.3     | 0.602  |
| Hypertension                          | 55.2            | 55.2       | 0       | 0.997  |
| Diabetes mellitus                     | 15.2            | 24.1       | 1.6     | 0.199  |
| Previous stroke                       | 20.9            | 24.1       | 0.2     | 0.675  |
| NIHSS score $\geq 16$ on arrival      | 14.0            | 10.3       | 0.3     | 0.582  |

| Thrombolysis-related adverse consequences in hospital | Immediate thrombolysis-related complications | Group difference |
|-------------------------------------------------------|---------------------------------------------|------------------|
| NIHSS score $\geq 16$ at 24 h after thrombolysis       | 5.7             | 20.7       | 9.8     | 0.002  |
| Worst LOC in the first seven days score $\geq 1$       | 25.0            | 60.7       | 16.8    | < 0.001 |
| UTI within 7 days of admission                         | 5.8             | 10.7       | 1.1     | 0.288  |
| Pneumonia within 7 days of admission                   | 11.0            | 35.7       | 14.5    | < 0.001 |
| UTI and/or pneumonia within 7 days of admission        | 13.5            | 39.3       | 13.5    | < 0.001 |
| LOS in HASU $\geq 2$ weeks                            | 34.7            | 66.7       | 6.4     | 0.012  |
| Mortality in hospital                                  | 13.0            | 41.4       | 17.2    | < 0.001 |
| Risk of malnutrition                                   | 0.5             | 0          | 0.1     | 0.708  |
| mRS score $\geq 4$ on discharge                       | 26.8            | 65.5       | 19.7    | < 0.001 |

| Level of care support planned at discharge            | Immediate thrombolysis-related complications | Group difference |
|-------------------------------------------------------|---------------------------------------------|------------------|
| Activities of daily living support required by patients | 17.6            | 20.0       | 0.1     | 0.815  |
| Joint care planning between health and social care for post-discharge management | 24.6            | 20.7       | 0.2     | 0.631  |
| New care home (permanent and temporary)               | 3.8             | 6.9        | 0.7     | 0.409  |
| New care home (permanent)                             | 2.6             | 6.9        | 1.7     | 0.182  |
| Palliative care by discharge date                     | 5.1             | 24.1       | 16.1    | < 0.001 |

*MCHS* National Institutes of Health for Stroke Scale, LOC level of consciousness, UTI urinary tract infection, LOS length of stay, HASU hyperacute stroke unit, mRS modified Rankin Scale
Compared with patients without immediate TRC (reference group), individuals with immediate TRC had greater adjusted risks of: moderately-severe or severe stroke (NIHSS score ≥ 16) at 24-h (5.7% vs 24.7%, OR 3.9, 95% CI 1.4–11.1); LOC score ≥ 1 in the first 7-days (29.0 vs 60.7, OR 4.6, 95% CI 2.1–10.2); urinary tract infection or pneumonia within 7-days of admission (13.5% vs 39.3%, OR 3.2, 95% CI 1.3–7.7); LOS on HASU ≥ 2 weeks (34.7% vs 66.7%, OR 5.2, 95% CI 1.5–18.4); mortality (13.0% vs 41.4%, OR 3.7, 95% CI 1.6–8.4); moderately-severe or severe disability (mRS score ≥ 4) at discharge (26.8% vs 65.5%, OR 4.7, 95% CI 2.1–10.9); palliative care requirement by discharge date (5.1% vs 24.1%, OR 5.1, 95% CI 1.7–15.7) (Table 3). The median LOS in HASU was longer (7-days vs 30 days, Kruskal–Wallis test: $\chi^2 = 8.9, p = 0.003$) while stroke severity did not improve (NIHSS score at 24-h post-thrombolysis minus NIHSS score at arrival $= -4$ vs 0, $\chi^2 = 24.3, p < 0.001$). Additional adjustment for time from stroke onset to thrombolysis and severity on arrival improved the associations only marginally.

**Discussion**

Although immediate TRC are well recognised [20, 21], there are no published data on their subsequent consequences. We observed that one in 15 patients acquired immediate TRC in this study. Such individuals, compared to those thrombolysed patients with no immediate complications, had 4–8 fold risk of adverse consequences including moderately-severe
Adverse consequences of immediate thrombolysis-related complications: a multi-centre...

**Fig. 3** Proportions of patients in different categories of worst level of consciousness score in the first 7-days following initial admission for stroke according to status of thrombolysis-related complications: blue bars indicate no complications, red bars indicate presence of complications.

**Table 3** Logistic regression to assess the risk of adverse consequences from immediate thrombolysis-related complications

|                          | OR   | 95% CI          | p    |
|--------------------------|------|-----------------|------|
| Model 1: unadjusted      |      |                 |      |
| NIHSS score ≥ 16 at 24 h after thrombolysis | 4.33 | 1.61–11.62      | 0.004|
| Worst LOC in the first seven days score ≥ 1 | 4.64 | 2.10–10.23      | <0.001|
| Pneumonia within 7 days of admission | 4.50 | 1.95–10.35      | <0.001|
| UTI or pneumonia within 7 days of admission | 4.15 | 1.84–9.33       | <0.001|
| LOS in HASU ≥ 2 weeks    | 3.77 | 1.26–11.27      | 0.018|
| Mortality in hospital    | 4.71 | 2.14–10.39      | <0.001|
| mRS score ≥ 4 on discharge | 5.20 | 2.35–11.51      | <0.001|
| Palliative care by discharge date | 6.00 | 2.28–15.83      | <0.001|
| Model 2: adjusted for age, sex, co-morbidities |      |                 |      |
| NIHSS score ≥ 16 at 24 h after admission | 3.90 | 1.37–11.07      | 0.011|
| Worst LOC in the first seven days score ≥ 1 | 4.14 | 1.82–9.40       | 0.001|
| Pneumonia within 7 days of admission | 3.14 | 1.29–7.66       | 0.012|
| UTI or pneumonia within 7 days of admission | 3.15 | 1.33–7.47       | 0.009|
| LOS in HASU ≥ 2 weeks    | 5.23 | 1.49–18.39      | 0.010|
| Mortality in hospital    | 3.65 | 1.59–8.41       | 0.002|
| mRS score ≥ 4 at discharge | 4.73 | 2.06–10.87      | <0.001|
| Palliative care by discharge date | 4.16 | 1.39–12.44      | 0.011|
| Model 3: as in model 2 plus time from onset to thrombolysis and NIHSS on arrival |      |                 |      |
| NIHSS score ≥ 16 at 24 h after admission | 5.55 | 1.65–18.74      | 0.006|
| Worst LOC in the first seven days score ≥ 1 | 7.44 | 2.77–19.96      | <0.001|
| Pneumonia within 7 days of admission | 3.83 | 1.47–10.02      | 0.006|
| UTI or pneumonia within 7 days of admission | 3.59 | 1.46–8.87       | 0.006|
| LOS in HASU ≥ 2 weeks    | 8.44 | 2.11–33.73      | 0.003|
| Mortality in hospital    | 3.67 | 1.59–8.43       | 0.002|
| mRS score ≥ 4 on discharge | 5.46 | 2.11–14.13      | <0.001|
| Palliative care by discharge date | 5.10 | 1.66–15.70      | 0.004|

*NHSS* National Institutes of Health for Stroke Scale, LOC level of consciousness, UTI urinary tract infection, LOS length of stay, HASU hyperacute stroke unit, mRS modified Rankin Scale.
to severe stroke (NIHSS score ≥ 16), worst LOC scores in
the first 7-days, pneumonia within 7-days of admission,
prolonged LOS, in-patient mortality, as well as moderately-
severe to severe disability (mRS score ≥ 4) and requiring
palliative care by discharge date. As far as we are aware,
there are no published reports on changes to stroke severity,
based on NIHSS scores, before and after immediate TRC.

Most studies concerning the management of patients
undergoing thrombolysis tend to focus on the overall out-
comes in all patients as a whole (with or without immedi-
ate TRC). Our study provided further evidence on a par-
ticular range of adverse consequences specifically arising
from patients who developed immediate complications after
thrombolysis, including a change of stroke severity, nosoco-
mial infections, disability and the need for palliative care by
dischage date, and in-patient mortality. All these adverse
consequences were independent of age, sex and a range of
major co-existing morbidities. We have also demonstrated
that the stroke severity in patients with immediate TRC did
not improve after thrombolysis while the severity in patients
who were free of immediate TRC was significantly reduced
after treatment. There were no group differences in level of
care required on discharge.

Variably reported figures of TRC in various studies are
likely to be due to differences in patient characteristics such
as age, underlying co-morbidities, disability and stroke
severity at presentation [22–24], as well as different manage-
ment approaches, particularly of symptomatic ICH [25–27].
The observation of older age and male predominance in
patients with immediate TRC is consistent with findings
from previous studies [28, 29]. Moreover, older adults have
increasingly been included for this treatment. Our study
showed the median age of patients with TRC (83 years) was
six years older than that of patients without immediate TRC
(77 years). There are conflicting reports on the benefit of
thrombolysis in older patients. In their study including those
over 80 years, Mishra et al. [7] observed thrombolysis to be
beneficial across all ages. A small study of 38 patients older
than 80 showed age does not affect outcome when adjusted
for stroke severity, time to thrombolysis, glucose level, and
history of coronary heart disease [30]. Meta-analysis also
showed age does not affect outcomes when compared with
controls [31], but a systematic review by the same group
found older age was associated with increased mortality and
reduced likelihood of regaining favourable outcomes [32].

These differences may arise from a higher rate of imme-
diate TRC that occur more frequently in older patients, as
observed in this study.

In recent years, the rates of thrombolysis amongst patients
admitted with AIS were 11.1% in Sweden [33] and 11–12% in
England and Wales [8]. These figures are slightly lower
than our figure (16.4%). The proportion of immediate TRC of 6.4%
observed in our study is comparable to those
previously reported [13, 34]. The NHS for England set a
long-term thrombolysis target of 20% a year (approximately
14,000 patients/year). Assuming that the immediate TRC
rate remains unchanged, the number of thrombolysis-related
complications is expected to be nearly double the current
number (approximately 14,000 × 6.4% = 900 patients/year).

Life expectancy in the UK, as for other industrialised
nations [35, 36], is increasing. At the same time in clinical
practice there is no age limit for thrombolysis. As a result,
according to our observations and the estimated projec-
tions listed above, more stroke survivors will be living with
dependency, causing a significant impact on the social and
healthcare systems. Our findings support the need for more
research; not only to lower the rate of immediate TRC but
also to prevent adverse outcomes among those who acquire
them, and to lower the number with immediate TRC to
improve their clinical consequences. Our observations of
symptomatic ICH as the most common complication of
thrombolysis is consistent with previous studies [13]. Recent
studies have provided insights into the mechanisms of intrac-
cerebral bleeding after thrombolysis in acute ischaemic stroke
and suggested the use of different biomarkers to predict its
occurrence [22–24, 37, 38]. Factors such as pre-treatment
normoglycaemia, female gender and lower stroke severity
are favourable predictors of clinical outcomes after throm-
bolysis [28, 39], while higher rates of post-thrombolysis ICH
increase with hypertension [28, 29, 40, 41], diabetes [28,
41], older age [28, 29], severe stroke [28, 40, 42], adverse
fibrinolytic profile at admission [43] and certain biomark-
ers such raised plasma cellular-fibronectin concentrations
[44]. The risk of symptomatic ICH following thrombolysis
is associated with pre-treatment antiplatelet agents in some
studies [28, 29], but equally this was not demonstrated in
others [28, 42]. In this study, the prevalence of AF was
higher in the group with immediate TRC than those with-
out (37.9% vs 18.5%, χ² = 6.5, p = 0.011). We found that
the proportions immediate TRC did not differ significantly
between patients who had antiplatelet treatment (10.6%) and
those who did not have the treatment (13.9%) prior to
thrombolysis (p = 0.857). In addition the rate of anticoagu-
ation therapy for their AF prior to thrombolysis was slightly
higher, but did not achieve significance and this may be due
to the small sample size or selection bias. Therefore these
observations cannot be interpreted with confidence. In cur-
rent practice, the dose of rtPA is based on the patient’s body
weight. A more individualised rtPA dose, adjusted according
to existing risk factors such as age and premorbid treatment,
may reduce bleeding such as ICH.

There are a number of published guidelines for the man-
agement of thrombolysis-related haemorrhage. The aim is to
reverse fibrinolysis with agents such as fresh frozen plasma,
anti-platelet effect with platelet transfusion, and coagulopa-
thy with agents including cryoprecipitate [45, 46]. The less
common orolingual angioedema is treated with antihistamines and methylprednisolone if required, and further escalation to adrenaline (epinephrine). Where angioedema fails to respond to drug therapy, intubation or tracheostomy may be necessary [47]. As far as we are aware, guidelines for management specifically for patients who acquired immediate TRC after hospital discharge are not available.

**Strengths and limitations**

The strength of the present study lies in its large cohort of patients derived from one of the largest NHS regions in the UK and who have similar characteristics to the rest of the UK [8]. Data were collected in accordance with the national SSNAP protocol and analysis took a range of confounding factors known to associate with stroke outcomes into account. The definitions of stroke severity (NIHSS) [17] and disability (mRS) [18] were based on validated tools commonly used for assessment of acute stroke. However, due to the relatively low rates, the number of patients receiving thrombolytic treatment thrombolysis was small. Caution should be taken when comparing results from other populations due to different approaches to the management of immediate TRC that may differ in outcomes.

In conclusion, the risk of nosocomial infections, worsening of stroke severity, longer HASU stay, disability and death is increased following immediate TRC. This finding has major implications for those centres seeking to increase their thrombolysis service to acute stroke patients.

**Acknowledgements** The authors wish to thank patients and all those who were involved in the surveys.

**Author contributions** TSH reviewed the topic related literature and performed the study concept and analysis design. GG, BA and PK performed the study coordination and data collection. TSH wrote the first draft, analysed, interpreted the data and revised the manuscript. CHF and PS edited the manuscript. GG, BA, JR, DF and PK checked, interpreted results and commented on the manuscript. All authors approved the final version.

**Funding** None.

**Data sharing statement** No additional data are available.

**Declarations**

**Conflict of interest** The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this paper.

**Ethical approval** This study does not require NHS Research Ethics Committee approval. This study was conducted in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Research involving human and animal participants** This article does not contain any studies with animals performed by any of the authors.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. European Stroke Organisation guidelines for stroke management: Update January 2009. Available from: http://www.eso-stroke.org/eso-stroke/education/education-guidelines.html. Accessed 3 Mar 2014
2. Intercollegiate Stroke Working Party. National Clinical Guidelines for Stroke. http://www.rcplondon.ac.uk/resources/stroke-guidelines. Accessed 2 Apr 2012
3. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC et al (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47:581–641
4. Fang MC, Cutler DM, Rosen AB (2010) Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med 5:406–409
5. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S et al (2013) Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcomes 6:543–549
6. Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ et al (2010) Intravenous alteplase for stroke in those older than 80 years old. Stroke 41:2568–2574
7. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA et al (2010) Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive. BMJ 341:c6046
8. Sentinel Stroke National Audit Programme. Springboard for Progress: The Seventh SSNAP Annual Report. https://www.strokeaudit.org/Documents/National/Clinical/Apr2019Mar2020/Apr2019Mar2020-AnnualReport.aspx
9. Rodriguez-Castro E, Lopez-Dequit I, Santamaria-Cadavid M, Arias-Rivas S, Rodriguez-Yanez M, Pumar JM et al (2018) Trends in stroke outcomes in the last ten years in a European tertiary hospital. BMC Neurol 18:164
10. Darehed D, Blom M, Glader EL, Niklasson J, Norrving B, Eriksen M (2020) In-hospital delays in stroke thrombolysis: every minute counts. Stroke 51:2536–2539
11. Wardlaw JM, Murray V, Berge E, Del Zoppo G, Sanderscock P, Lindley RL et al (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379:2364–2372
12. Bustamante A, Garcia-Berrocoso T, Rodriguez N, Llombart V, Ribo M, Molina C et al (2016) Ischemic stroke outcome: a review of the influence of post-stroke complications within the different scenarios of stroke care. Eur J Intern Med 29:9–21

13. Bray BD, Campbell J, Hoffmann A, Tyrrell PJ, Wolfe CD, Rudd AG (2013) Stroke thrombolysis in England: an age stratified analysis of practice and outcome. Age Ageing 42:240–245

14. Royal College of Physicians. Clinical effectiveness and evaluation unit on behalf of the intercollegiate stroke working party. SSNAP January–March 2016. Public Report. https://www.strokeaudit.org/Documents/National/AcuteOrg/2016/2016-AOANationalReport.aspx. Accessed 15 Jan 2021

15. Han TS, Fry CH, Fluck D, Affley B, Gulli G, Barrett C et al (2018) Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK. BMJ Open 8:e022558

16. Han TS, Gulli G, Affley B, Fluck D, Fry CH, Barrett C et al (2019) New evidence-based A1, A2, A3 alarm time zones for transferring thrombolysed patients to hyper-acute stroke units: faster is better. Neurol Sci 40:1659–1665

17. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J et al (1989) Measurements of acute cerebral infarction: a clinical examination. Stroke 20:864–870

18. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607

19. Wang YX, Li YQ, Chen Y, Zhang CH, Dong Z, Wang Z et al (2018) Analysis of related factors of oedolong angiodoea after rt-PA intravenous thrombolytic therapy. Eur Rev Med Pharmacol Sci 22:1478–84

20. Han TS, Fry CH, Gulli G, Affley B, Robin J, Irvin-Sellers M et al (2020) Prestroke disability predicts adverse poststroke outcome: a registry-based prospective cohort study of acute stroke. Stroke 51:594–600

21. Nesselroth D, Gilad R, Namneh M, Avishay S, Eilam A (2018) Estimation of seizures prevalence in ischemic strokes after thrombolytic therapy. Seizure 62:91–94

22. Mazya M, Eggido JA, Ford GA, Lees KR, Mikulik R, Toni D et al (2012) Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 43:1524–1531

23. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM et al (2012) Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 43:2293–2299

24. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P et al (2012) The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke 43:1315–1322

25. Goldstein JM, Marrero M, Masrur S, Perverz M, Barrocas AM, Abdullah A et al (2010) Management of thrombosis-associated symptomatic intracerebral hemorrhage. Arch Neuro 67:965–969

26. French KF, White J, Hoesch RE (2012) Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care 17:107–111

27. YaghI S, Eisenberger A, Willey JZ (2014) Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol 71:1181–1185

28. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M et al (2002) Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA stroke survey. Circulation 105:1679–1685

29. Larrue V, von Kummer RR, Müller A, Bluhmki E (2001) Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 32:438–441

30. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B et al (2005) Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 65:1795–1798

31. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Stroke Thrombolysis Trialists’ Collaborative Group et al (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384:1929–1935

32. Engelter ST, Bonati LH, Lyter PA (2006) Intraventricular thromboly- sis in stroke patients of ≥80 versus <80 years of age—a systematic review across cohort studies. Age Ageing 35:572–580

33. Vestesson E, Bray B, James M, Paley L, Kavanagh M, Tyrrell P et al (2016) An international comparison of thrombolysis in England and Wales, and Sweden using national registers. Int J Stroke 11:38

34. El Tawil S, Muir KW (2017) Thrombolysis and thrombectomy for acute ischaemic stroke. Clin Med 17:161–165

35. Christensen V, Dobblhammer G, Rau R, Vaupel JW (2009) Ageing populations: the challenges ahead. Lancet 374:1196–1208

36. Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M (2017) Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet 389:1323–1335

37. Lopes D, Nighoghossian N (2008) Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 79:1093–1099

38. Karaszkewi B, Houlden H, Smith EE, Markus HS, Charidimou A, Levi C et al (2015) What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers. J Neurol Neurosurg Psychiatry 86:1127–1136

39. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M et al (2001) Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 57:474–480

40. Gilligan AK, Markus R, Read S, Srikanth V, Hirano T, Fitt G et al (2002) Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 33:2236–2242

41. Derex L, Hermier M, Adeleine P, Pialat JB, Wiart M, Berthezene Y et al (2005) Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 76:70–75

42. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis L, Sobesky J et al (2003) Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 16:183–190

43. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamaria E, Quintana M et al (2004) Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35:2123–2127

44. Castellanos M, Leira R, Serrat J, Blanco M, Pedraza S, Castillo J et al (2004) Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35:1671–1676

45. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, On behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology et al (2015) Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for
healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46:2032–60
46. Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P et al (2017) Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 48:e343–e361
47. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.